Clinical trial
Nicotinic Modulation of the Cognitive Control System in Late-Life Depression (R33 Phase)
NCT05746273 is registered in ClinicalTrials.gov with Vanderbilt University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Nicotinic Modulation of the Cognitive Control System in Late-Life Depression (R33 Phase)
- Lead sponsor
- Vanderbilt University Medical Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 15, 2023
- Completion date
- July 9, 2026
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.